Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07UKF
|
|||
| Former ID |
DIB001168
|
|||
| Drug Name |
VBY-129
|
|||
| Synonyms |
Cathepsin S inhibitor (oral, psoriasis), Virobay
Click to Show/Hide
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 1 | [1] | |
| Crohn disease [ICD-11: DD70; ICD-10: K50, K50.9; ICD-9: 555] | Phase 1 | [2] | ||
| Neuropathic pain [ICD-11: 8E43.0] | Phase 1 | [3] | ||
| Company |
Virobay Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin S (CTSS) | Target Info | Inhibitor | [4] |
| KEGG Pathway | Lysosome | |||
| Phagosome | ||||
| Antigen processing and presentation | ||||
| Tuberculosis | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Reactome | Endosomal/Vacuolar pathway | |||
| Degradation of the extracellular matrix | ||||
| Trafficking and processing of endosomal TLR | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | Class I MHC mediated antigen processing & presentation | |||
| Trafficking and processing of endosomal TLR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of ViroBay. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of ViroBay. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.